Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Formulary Design Should Prevent Risk Selection – Rep. Waxman

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS faces a dilemma in trying to satisfy both plan providers and manufacturers, Waxman acknowledges, and says that the agency should ensure that formularies do not discourage use by high-cost beneficiaries.

You may also be interested in...



Humana Sees "Very Solid" Business Opportunity in Medicare Part D

Humana's "footprint" area includes 16 mil. Medicare eligibles, many currently uncovered by a Medicare Advantage PPO. The insurer plans a stand-alone drug plan in 31 regions and a Medicare Advantage plan in 16 regions. Providing its own in-house PBM services could offer an advantage, the company suggests.

Humana Sees "Very Solid" Business Opportunity in Medicare Part D

Humana's "footprint" area includes 16 mil. Medicare eligibles, many currently uncovered by a Medicare Advantage PPO. The insurer plans a stand-alone drug plan in 31 regions and a Medicare Advantage plan in 16 regions. Providing its own in-house PBM services could offer an advantage, the company suggests.

Reimportation Is "Phony" Issue, Waxman Says, But Driven By Real Pricing Problems

Reimportation is not the solution to high U.S. drug prices, Rep. Henry Waxman (D-Calif.) said

Related Content

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel